In vivo assessment of a delayed release formulation of larazotide acetate indicated for celiac disease using a porcine model

There is no FDA approved therapy for the treatment of celiac disease (CeD), aside from avoidance of dietary gluten. Larazotide acetate (LA) is a first in class oral peptide developed as a tight junction regulator, which is a lead candidate for management of CeD. A delayed release formulation was tes...

Descripción completa

Detalles Bibliográficos
Autores principales: Enomoto, Hiroko, Yeatts, James, Carbajal, Liliana, Krishnan, B. Radha, Madan, Jay P., Laumas, Sandeep, Blikslager, Anthony T., Messenger, Kristen M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8041193/
https://www.ncbi.nlm.nih.gov/pubmed/33844694
http://dx.doi.org/10.1371/journal.pone.0249179

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8041193/
https://www.ncbi.nlm.nih.gov/pubmed/33844694
http://dx.doi.org/10.1371/journal.pone.0249179

Ejemplares similares